Cognitive Assessment Tools for Individuals With Huntington's Disease.
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
• Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
• Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
• A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
• Vision and hearing sufficient for compliance with tests.
• On a stable dose of medications for 30 days prior to the time of signing the informed consent form.